News & Views

Telix is pleased to announce that it has entered into a conditional purchase agreement with Eckert & Ziegler Strahlen and Medizintechnik Aktiengesellschaft to acquire a licensed radiopharmaceutical production facility in Seneffe, Belgium.

Telix is pleased to share the company had a pre-NDA meeting with the United States Food and Drug Administration (FDA) on the 24th of July to discuss the Company’s plan for the submission of a New Drug Application (NDA) for TLX591-CDx, (kit for the preparation of 68Ga-PSMA, trademarked as illumet™ in the United States).

Telix Pharmaceuticals Limited is pleased to provide appendix 4D half-year report for the six months ended 30th June 2019.

Telix Pharmaceuticals Ltd is pleased to announce Appendix 3B – Issue of shares under Share Purchase Plan (SPP).

Telix Pharmaceuticals Limited is pleased to advise that, at closing on Friday 16th August 2019, subscriptions under the Company’s Share Purchase Plan (“SPP”) totaled approximately $9.6 million.

Telix Pharmaceuticals Limited is pleased to provide its Annual Report 2018.

Telix Pharmaceuticals Limited is pleased to provide a detailed Program Update January 2019.

Telix Pharmaceuticals Limited (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), has successfully raised $50 million following the close of its fully underwritten Initial Public Offering (IPO). The IPO was strongly supported by institutional investors internationally and domestically, as well as by retail investors in Australia.

Telix Pharmaceuticals Limited is pleased to announce the opening of its Initial Public Offering to raise A$50 million.

Telix Pharmaceuticals is pleased to announce it has filed a $50 million Underwritten Initial Public Offering.